Table 2. Disease characteristics among women with IBD.
| Characteristic | Crohn's Disease n (%) n=59 |
Ulcerative Colitis n (%) n=65 |
|---|---|---|
| Extent/Location of Disease | ||
| Proctitis (UC) | 9 (13.9) | |
| Left-sided (UC) | 21 (32.3) | |
| Pan-colitis (UC) | 24 (36.9) | |
| Unknown (UC) | 11 (16.9) | |
| Ileal (CD) | 10 (17.0) | |
| Colonic (CD) | 15 (25.4) | |
| Ileocolonic (CD) | 29 (49.2) | |
| Unknown (CD) | 5 (8.5) | |
| Perianal CD | 11 (18.6) | |
| Ileal pouch-anal anastomosis | 10 (15.4) | |
| Other abdominal surgery for IBD | 16 (27.1) | 1 (1.5) |
| Medications during pregnancy | ||
| None | 12 (20.3) | 15 (23.1) |
| Maintenance therapy | ||
| Rectal 5-ASA monotherapy | 0 (0.0) | 9 (13.8) |
| Oral 5-ASA monotherapy | 19 (32.2) | 11 (16.9) |
| Rectal + oral 5-ASA | 1 (1.7) | 11 (16.9) |
| Thiopurine monotherapy | 7 (11.9) | 4 (6.2) |
| Thiopurine + 5-ASA | 11 (18.6) | 9 (13.8) |
| Anti-TNF Monotherapy | 5 (8.5) | 0 (0.0) |
| Thiopurine + anti-TNF | 3 (5.1) | 1 (1.5) |
| Thiopurine + anti-TNF + 5-ASA | 1 (1.7) | 0 (0.0) |
| Steroid enemas* | 2 (3.4) | 4 (6.15) |
| Any systemic steroid use* | 3 (5.1) | 5 (7.7) |
| Antibiotics* | 1 (1.7) | 3 (4.6) |
| Gastroenterologist | ||
| General | 23 (39.0) | 21 (32.2) |
| Inflammatory bowel disease | 33 (55.9) | 34 (52.3) |
| None | 0 (0.0) | 5 (7.7) |
| Unknown | 3 (5.1) | 5 (7.7) |
| Disease activity | ||
| Active disease | ||
| Before pregnancy | 9 (15.3) | 18 (27.7) |
| During pregnancy and/or delivery | 14 (23.7) | 27 (41.5) |
| Inactive disease | 41 (69.5) | 32 (49.2) |
*
N (%)calculated separately than from maintenance therapies